GLP-1 drugs linked to accelerated bone loss, osteoporosis risk in new five-year analysis
New research analyzing 146,000 patient records found GLP-1 users developed osteoporosis at a 29% higher relative risk than nonusers.
A February 2026 study linked GLP-1 drugs to an 11% higher risk of fragility fractures in older adults.
Clinical trial data showed semaglutide reduced hip bone density by 2.6% and spine density by 2.1% over 52 weeks.
Appetite suppression reduces calcium, vitamin D, magnesium and protein intake that bone tissue requires for maintenance.
Experts recommend resistance exercise, calcium supplementation and protein intake of 1.2-1.6 grams per kilogram daily for users.
Read Full Article: https://www.naturalnews.com/2026-06-02-glp1-drugs-linked-to-accelerated-bone-loss-osteoporosis.html
